Emerging drugs in metastatic breast cancer

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Weiss RB, Woolf SH, Demakos E, et al. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol 2003;21:1825-35
   PubMed Web of Science ®Google Scholar
• Chia SK, Speers CH, D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-9
   PubMed Web of Science ®Google Scholar
• Contents of the SEER Cancer Statistics Review, 1975-2005. National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2005/sections.html [Last accessed 1 September 2008
   Google Scholar
• Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-91
   PubMed Web of Science ®Google Scholar
• Vollenweider-Zerargui L, Barrelet L, Wong Y, et al. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer 1986;57:1171-80
   PubMed Web of Science ®Google Scholar
• Kufe DW, Bast RC, Hait WN, et al. Cancer Medicine 7. BC Decker Inc. Hamilton, London, 2006
   Google Scholar
• Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-67
   PubMed Web of Science ®Google Scholar
• Milla-Santos A, Milla L, Portella J, et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, Phase III study. Am J Clin Oncol 2003;26:317-22
   PubMed Web of Science ®Google Scholar
• Deshmane V, Krishnamurthy S, Melemed AS, et al. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 2007;25:4967-73
   PubMed Web of Science ®Google Scholar
• Milla-Santos A, Milla L, Rallo L, et al. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 2001;65:119-24
   PubMed Web of Science ®Google Scholar
• Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995;13:2556-66
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bria E, Giannarelli D, et al. Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 2006;94:1789-96
   PubMed Web of Science ®Google Scholar
• Goss PE, Gwyn KM. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994;12:2460-70
   PubMed Web of Science ®Google Scholar
• Saphner T, Troxel AB, Tormey DC, et al. Phase II study of goserelin for patients with postmenopausal metastatic breast cancer. J Clin Oncol 1993;11:1529-35
   PubMed Web of Science ®Google Scholar
• Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V.2.2008. Available from: www.nccn.org
   Google Scholar
• Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13
   PubMed Web of Science ®Google Scholar
• Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-38
   PubMed Web of Science ®Google Scholar
• Lundgren S. Progestins in breast cancer treatment. A review. Acta Oncol 1992;31:709-22
   PubMed Web of Science ®Google Scholar
• Allegra JC, Kiefer SM. Mechanisms of action of progestational agents. Semin Oncol 1985;12:2003-5
   Google Scholar
• Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res 2002;4:133-6
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Smith TL, Legha SS, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983;1:776-86
   PubMed Web of Science ®Google Scholar
• George SL, Hoogstraten B. Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J Natl Cancer Inst 1978;60:731-6
   PubMed Web of Science ®Google Scholar
• Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-92
   Google Scholar
• Carrick S, Parker S, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005;2:CD003372
   PubMedGoogle Scholar
• O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812-23
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-7
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993;4:19-26
   PubMed Web of Science ®Google Scholar
• Dawood SS, Kristine B, Hortobagyi GN, et al. Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: An institutional based review. ASCO Meeting Abstracts. J Clin Oncol 2008;26:1018
   Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
   PubMed Web of Science ®Google Scholar
• Gori S, Colozza M, Mosconi AM, et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 2004;90:36-40
   PubMed Web of Science ®Google Scholar
• Schaller G, Fuchs I, Gonsch T, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007;25:3246-50
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95
   PubMed Web of Science ®Google Scholar
• Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter Phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96:759-69
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 2008;35:S1-14; quiz S39
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd. Preclinical investigations with epothilones in breast cancer models. Semin Oncol 2008;35:S15-21; quiz S39
   PubMed Web of Science ®Google Scholar
• Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37
   PubMed Web of Science ®Google Scholar
• Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-7
   PubMed Web of Science ®Google Scholar
• Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14
   PubMed Web of Science ®Google Scholar
• Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406
   PubMed Web of Science ®Google Scholar
• Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7
   PubMed Web of Science ®Google Scholar
• Vahdat LT. Clinical studies with epothilones for the treatment of metastatic breast cancer. Semin Oncol 2008;35:S22-30; quiz S40
   PubMed Web of Science ®Google Scholar
• Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006;42:24-30
   PubMed Web of Science ®Google Scholar
• Elsheikh SE, Green AR, Rakha EA, et al. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 2008;99:327-34
   PubMed Web of Science ®Google Scholar
• Altundag K, Bulut N, Dizdar O, et al. Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007. Breast Cancer Res Treat 2006;100:329-30
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803
   PubMed Web of Science ®Google Scholar
• Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52:606-23
   PubMed Web of Science ®Google Scholar
• Perez EA, Hillman DW, Mailliard JA, et al. Randomized Phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004;22:2849-55
   PubMed Web of Science ®Google Scholar
• Frasci G, D'Aiuto G, Thomas R, et al. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients. Oncology 2005;68:391-7
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A, Martin M, Harbeck N, et al. A randomized, double-blind, Phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res 2007;13:3652-9
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A, Theodoulou M, Rowland K, et al. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: Phase II study. Clin Breast Cancer 2006;7:380-5
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy JA, Clark RS, Blum JL, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005;6:143-9
   PubMedGoogle Scholar
• Ma CX, Steen P, Rowland KM, et al. A Phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Ann Oncol 2006;17:226-31
   PubMed Web of Science ®Google Scholar
• Bilancia D, Rosati G, Dinota A, et al. Lapatinib in breast cancer. Ann Oncol 2007;18(Suppl 6):vi26-30
   PubMed Web of Science ®Google Scholar
• Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Storniolo AM, Franco S, et al. A Phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19:1068-74
   PubMed Web of Science ®Google Scholar
• Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008;26:1066-72
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
   PubMed Web of Science ®Google Scholar
• Perez E, Byrne J, Hammond I, et al. E: Cardiac safety experience in 3127 patients treated with lapatinib [abstract 1420]. Ann Oncol 2006;17:ix70
   Google Scholar
• Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-9
   PubMed Web of Science ®Google Scholar
• Boccardo F, Kaufman B, Baselga J, et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). ASCO Meeting Abstracts. J Clin Oncol 2008;26:1094
   Google Scholar
• Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37
   PubMed Web of Science ®Google Scholar
• Cortes J, Baselga J, Kellokumpu-Lehtinen P, et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. ASCO Meeting Abstracts. J Clin Oncol 2005;23:3068
   Web of Science ®Google Scholar
• Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007;99:694-705
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Fumoleau P, Verma S, et al. Results of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. ASCO Meeting Abstracts. J Clin Oncol 2008;26:1026
   Web of Science ®Google Scholar
• Holden SN, Beeram M, Krop IE, et al. A Phase I Tudy of weekly dosing of Trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer [abstract 1029]. J Clin Oncol 2008;126:48s
   Google Scholar
• Ferrara N,Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW, et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9
   PubMed Web of Science ®Google Scholar
• Sledge G, Miller K, Moisa C, Gradishar W. Safety and efficacy of capecitabine plus bevacizumab as first-line in metastatic breast cancer. ASCO Meeting Abstracts. J Clin Oncol 2007;25:1013
   Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Ramaswamy B, Elias AD, Kelbick NT, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006;12:3124-9
   PubMed Web of Science ®Google Scholar
• Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. ASCO Meeting Abstracts. J Clin Oncol 2008;26:1011
   Google Scholar
• Danso MA, Blum JL, Robert NJ, et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. ASCO Meeting Abstracts. J Clin Oncol 2008;26:1075
   Google Scholar
• Espinós J, Olier-Garate C, Aramendia JM, et al. Efficacy of the combination of irinotecan and bevacizumab in heavily pretreated metastatic breast cancer. ASCO Meeting Abstracts. J Clin Oncol 2008;26:12001
   Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-6
   PubMed Web of Science ®Google Scholar
• Bianchi GV, Loibl S, Zamagni C, et al. Phase II multicenter trial of sorafenib in the treatment of patients with metastatic breast cancer. ASCO 2007 Breast Cancer Symposium [abstract 164]
   Google Scholar
• Rugo HS, Stopeck A, Joy AA, et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). ASCO Meeting Abstracts. J Clin Oncol 2007;25:1003
   PubMed Web of Science ®Google Scholar
• Faratian D, Bartlett J. Predictive markers in breast cancer–the future. Histopathology 2008;52:91-8
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Jonat W, Fasching P, et al. A multicentre Phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;89:165-72
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Valero V, Mangalik A, et al. A Phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). ASCO Meeting Abstracts. J Clin Oncol 2008;26:1012
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized Phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007;106:32
   Web of Science ®Google Scholar
• Amar S, Roy V, Perez EA: Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat 2008 May 9. [Epub ahead of print]
   Google Scholar
• Bell R, Feng-Yi F, Barrios C, et al. Trastuzumab re-treatment in patients who relapse following adjuvant trastuzumab therapy: Preliminary efficacy data from the RHEA trial. ASCO 2007 Breast Cancer Symposium [abstract 245]
   Google Scholar
• Forbes JF. The control of breast cancer: the role of tamoxifen. Semin Oncol 1997;24:S1-5-S1-19
   Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-411
   PubMed Web of Science ®Google Scholar
• Vorobiof DA, Kleeberg UR, Perez-Carrion R, et al. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer. Ann Oncol 1999;10:1219-25
   PubMed Web of Science ®Google Scholar
• Crighton IL, Dowsett M, Lal A, et al. Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects. Br J Cancer 1989;60:644-8
   PubMed Web of Science ®Google Scholar
• Garcia-Giralt E, Beuzeboc P, Dieras V, et al. Phase II trial of decapeptyl (D-TRP-6), a potent luteinizing hormone-releasing hormone analogue in untreated advanced breast cancer. Am J Clin Oncol 1996;19:455-8
   PubMed Web of Science ®Google Scholar
• Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000;18:724-33
   PubMed Web of Science ®Google Scholar
• Perez DJ, Harvey VJ, Robinson BA, et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 1991;9:2148-52
   PubMed Web of Science ®Google Scholar
• Coleman RE, Biganzoli L, Canney P, et al. A randomised Phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006;42:882-7
   PubMed Web of Science ®Google Scholar
• Jones SE, Erban J, Overmoyer B, et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542-51
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63:217-36
   PubMed Web of Science ®Google Scholar
• Bunnell CA, Winer EP. Oral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park) 1998;12:39-43
   PubMed Web of Science ®Google Scholar
• Dent S, Messersmith H, Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat 2008;108:319-31
   PubMed Web of Science ®Google Scholar
• Buzdar AU. Chemotherapeutic approaches to advanced breast cancer. Semin Oncol 1988;15:65-70
   PubMed Web of Science ®Google Scholar
• Mano M. Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. Cancer Treat Rev 2006;32:106-18
   PubMed Web of Science ®Google Scholar
• Navarro M, Bellmunt J, Balana C, et al. Mitomycin-C and vinblastine in advanced breast cancer. Oncology 1989;46:137-42
   PubMed Web of Science ®Google Scholar
• Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001;2:190-208; discussion 209
   PubMedGoogle Scholar
• Ron IG, Vishne TH, Kraminsky N, et al. Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer. Am J Clin Oncol 1999;22:35-7
   PubMed Web of Science ®Google Scholar
• Steinberg M. Ixabepilone: A novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Clin Ther 2008;30:1590-617
   PubMed Web of Science ®Google Scholar
• A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol 1991;9:305-12
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J Clin Oncol 2003;21:968-75
   PubMed Web of Science ®Google Scholar
• Langley RE, Carmichael J, Jones AL, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 2005;23:8322-30
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen MB, et al. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007;43:877-84
   PubMed Web of Science ®Google Scholar
• Fuentes H, Calderillo G, Alexander F, et al. Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anticancer Drugs 2006;17:565-70
   PubMed Web of Science ®Google Scholar
• Andre F, Campone M, Hurvitz MA, et al. Multicenter Phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab [abstract no 1003]. J Clin Oncol 2008;26:41s
   Web of Science ®Google Scholar
• Vahdat LT, C. T, Allison MK, et al. Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy [abstract no 1084]. J Clin Oncol 2008;26:62s
   Google Scholar
• Krop IE, Miller KD, Zon RT, et al. A Phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen: HOG BRE05-97. J Clin Oncol 2008;26:42s
   Google Scholar
• Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer [abstract 1016]. J Clin Oncol 2008;26:45s
   Google Scholar
• Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) [abstract 1027]. J Clin Oncol 2008;26:47s
   Google Scholar
• Sylvester L, Laufman L, Jabboury K, et al. Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T) [abstract 11508]. J Clin Oncol 2007;26:
   Google Scholar
• Phase I/ II Study of AZD2281 Given in Combination with Paclitaxel in Metastatic Triple Negative Breast Cancer. Available from: www.clinicaltrials.gov ClinicalTrials.gov Identifier: NCT00707707
   Google Scholar
• Zelek L, Yovine A, Brain E, et al. A Phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006;94:1610-4
   PubMed Web of Science ®Google Scholar
• Randomized Phase II Trial of Letrozole (Femara) with or without Dasatinib (Sprycel) as First-Line Treatment for Patients with Post-Menopausal Metastatic Breast Cancer (MBC). Available from: www.clinicaltrials.gov ClinicalTrials.gov Identifier: NCT00696072
   Google Scholar